Modality
Gene Therapy
MOA
IL-17i
Target
PD-1
Pathway
mTOR
Prostate CaUC
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
~May 2018
→ ~Aug 2019
Phase 3
~Nov 2019
→ ~Feb 2021
NDA/BLA
May 2021
→ Nov 2027
NDA/BLACurrent
NCT04033477
1,052 pts·UC
2021-05→2027-11·Terminated
1,052 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-241.7y awayPh3 Readout· UC
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2027-11-24 · 1.7y away
UC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04033477 | NDA/BLA | UC | Terminated | 1052 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 |